Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors
Retrieved on:
Monday, November 8, 2021
Audit committee, Female, Sumitomo Dainippon Pharma, Roche, Food, Oregon Health Plan, Growth, Anosy, COVID-19, Pain, University, Review, Uterine fibroid, Gonadotropin-releasing hormone, Pregnancy, Infertility, Oregon, Woman, GLOBE, New Drug Application, Stanford University, Internal medicine, Patient, FDA, Adult, Roivant Sciences, UCSF, Health care, Private Securities Litigation Reform Act, Oregon Health & Science University, San Francisco, Norethisterone, Endometriosis, Twitter, SEC, Texas Health and Science University, United States, Man, Medication, Risk, Senior, University of California, San Francisco, Board, LinkedIn, Breast cancer, NYSE, Leadership, Drug development, Pharmaceutical industry
as an independent member of the companys Board of Directors.
Key Points:
- as an independent member of the companys Board of Directors.
- In addition to her Board appointment, Dr. Valente will chair the Boards Nominating and Corporate Governance Committee and be a member of the Audit Committee.
- We are excited to welcome Dr. Valente to our Board, said David Marek, Chief Executive Officer of Myovant Sciences, Inc.
- I am honored to serve on the Board of Directors of Myovant Sciences, said Dr. Valente.